Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab

Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well‐tolerated, and easy to manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Binet, Quentin, Hammer, Frank D., Rocrelle, Olivia, Peeters, André, Scavée, Christophe, Hermans, Cedric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889252/
https://www.ncbi.nlm.nih.gov/pubmed/29636943
http://dx.doi.org/10.1002/ccr3.1446
_version_ 1783312670604132352
author Binet, Quentin
Hammer, Frank D.
Rocrelle, Olivia
Peeters, André
Scavée, Christophe
Hermans, Cedric
author_facet Binet, Quentin
Hammer, Frank D.
Rocrelle, Olivia
Peeters, André
Scavée, Christophe
Hermans, Cedric
author_sort Binet, Quentin
collection PubMed
description Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well‐tolerated, and easy to manage in an emergency room or stroke unit.
format Online
Article
Text
id pubmed-5889252
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58892522018-04-10 Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab Binet, Quentin Hammer, Frank D. Rocrelle, Olivia Peeters, André Scavée, Christophe Hermans, Cedric Clin Case Rep Case Reports Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well‐tolerated, and easy to manage in an emergency room or stroke unit. John Wiley and Sons Inc. 2018-02-27 /pmc/articles/PMC5889252/ /pubmed/29636943 http://dx.doi.org/10.1002/ccr3.1446 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Binet, Quentin
Hammer, Frank D.
Rocrelle, Olivia
Peeters, André
Scavée, Christophe
Hermans, Cedric
Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
title Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
title_full Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
title_fullStr Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
title_full_unstemmed Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
title_short Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
title_sort systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889252/
https://www.ncbi.nlm.nih.gov/pubmed/29636943
http://dx.doi.org/10.1002/ccr3.1446
work_keys_str_mv AT binetquentin systemicthrombolysisandendovascularthrombectomyinsevereacuteischemicstrokeafterdabigatranreversalwithidarucizumab
AT hammerfrankd systemicthrombolysisandendovascularthrombectomyinsevereacuteischemicstrokeafterdabigatranreversalwithidarucizumab
AT rocrelleolivia systemicthrombolysisandendovascularthrombectomyinsevereacuteischemicstrokeafterdabigatranreversalwithidarucizumab
AT peetersandre systemicthrombolysisandendovascularthrombectomyinsevereacuteischemicstrokeafterdabigatranreversalwithidarucizumab
AT scaveechristophe systemicthrombolysisandendovascularthrombectomyinsevereacuteischemicstrokeafterdabigatranreversalwithidarucizumab
AT hermanscedric systemicthrombolysisandendovascularthrombectomyinsevereacuteischemicstrokeafterdabigatranreversalwithidarucizumab

Ejemplares similares